A double-blinded, randomized, vehicle-controlled study to access skin tolerability and efficacy of an anti-inflammatory moisturizer in treatment of acne with 0.1% adapalene gel

Introduction: Topical retinoids are considered to be the first-line agents and maintenance therapy of acne; however, irritation side effects are major concern issues. Noncomedogenic moisturizers are sometimes added to relieve cutaneous irritations. This study aimed to compare tolerability and effica...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The Journal of dermatological treatment Ročník 27; číslo 2; s. 140 - 145
Hlavní autoři: Chularojanamontri, Leena, Tuchinda, Papapit, Kulthanan, Kanokvalai, Varothai, Supenya, Winayanuwattikun, Waranaree
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Taylor & Francis 03.03.2016
Témata:
Acne
Acne Vulgaris - drug therapy
adapalene
Adapalene - therapeutic use
Administration, Topical
Adult
Anti-Inflammatory Agents - therapeutic use
Chalcones - administration & dosage
Dermatologic Agents - therapeutic use
Double-Blind Method
Female
Gels
Humans
Male
Medication Adherence
moisturizer containing licochalcone
Prospective Studies
Skin - pathology
treatment
Young Adult
treatment
moisturizer containing licochalcone
Acne
adapalene
ISSN:0954-6634, 1471-1753
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Introduction: Topical retinoids are considered to be the first-line agents and maintenance therapy of acne; however, irritation side effects are major concern issues. Noncomedogenic moisturizers are sometimes added to relieve cutaneous irritations. This study aimed to compare tolerability and efficacy of moisturizers containing licochalcone A, l-carnitine and 1,2-decanediol (active formulation) with a placebo in mild to moderate severe acne in Asian subjects. Methods: This was an 8-week double-blind, prospective, randomized controlled study. All patients (n = 120) were randomized equally into three groups: (A) adapalene gel, (B) adapalene gel with the active formulation and (C) adapalene gel with the placebo. The severity of acne, skin bioengineering measurements and skin tolerability were recorded during the study. Results: Compared to baseline, the active formulation group showed significant reductions in inflammatory lesions and total lesions at the end of the study without flare-up. Moreover, skin irritations were less detected than in the other two groups by corneometer and transepidermal water loss measurements. Conclusions: The concomitant usage of adapalene gel and the moisturizer containing licochalcone A, l-carnitine and 1,2-decanediol could reduce undesirable side effects without interfering the efficacy of adapalene. This moisturizer may be superior to placebo to prevent cutaneous irritations and enhance patients' adherence to acne medications.
AbstractList Topical retinoids are considered to be the first-line agents and maintenance therapy of acne; however, irritation side effects are major concern issues. Noncomedogenic moisturizers are sometimes added to relieve cutaneous irritations. This study aimed to compare tolerability and efficacy of moisturizers containing licochalcone A, l-carnitine and 1,2-decanediol (active formulation) with a placebo in mild to moderate severe acne in Asian subjects. This was an 8-week double-blind, prospective, randomized controlled study. All patients (n = 120) were randomized equally into three groups: (A) adapalene gel, (B) adapalene gel with the active formulation and (C) adapalene gel with the placebo. The severity of acne, skin bioengineering measurements and skin tolerability were recorded during the study. Compared to baseline, the active formulation group showed significant reductions in inflammatory lesions and total lesions at the end of the study without flare-up. Moreover, skin irritations were less detected than in the other two groups by corneometer and transepidermal water loss measurements. The concomitant usage of adapalene gel and the moisturizer containing licochalcone A, l-carnitine and 1,2-decanediol could reduce undesirable side effects without interfering the efficacy of adapalene. This moisturizer may be superior to placebo to prevent cutaneous irritations and enhance patients' adherence to acne medications.
Introduction: Topical retinoids are considered to be the first-line agents and maintenance therapy of acne; however, irritation side effects are major concern issues. Noncomedogenic moisturizers are sometimes added to relieve cutaneous irritations. This study aimed to compare tolerability and efficacy of moisturizers containing licochalcone A, l-carnitine and 1,2-decanediol (active formulation) with a placebo in mild to moderate severe acne in Asian subjects. Methods: This was an 8-week double-blind, prospective, randomized controlled study. All patients (n = 120) were randomized equally into three groups: (A) adapalene gel, (B) adapalene gel with the active formulation and (C) adapalene gel with the placebo. The severity of acne, skin bioengineering measurements and skin tolerability were recorded during the study. Results: Compared to baseline, the active formulation group showed significant reductions in inflammatory lesions and total lesions at the end of the study without flare-up. Moreover, skin irritations were less detected than in the other two groups by corneometer and transepidermal water loss measurements. Conclusions: The concomitant usage of adapalene gel and the moisturizer containing licochalcone A, l-carnitine and 1,2-decanediol could reduce undesirable side effects without interfering the efficacy of adapalene. This moisturizer may be superior to placebo to prevent cutaneous irritations and enhance patients' adherence to acne medications.
INTRODUCTIONTopical retinoids are considered to be the first-line agents and maintenance therapy of acne; however, irritation side effects are major concern issues. Noncomedogenic moisturizers are sometimes added to relieve cutaneous irritations. This study aimed to compare tolerability and efficacy of moisturizers containing licochalcone A, l-carnitine and 1,2-decanediol (active formulation) with a placebo in mild to moderate severe acne in Asian subjects.METHODSThis was an 8-week double-blind, prospective, randomized controlled study. All patients (n = 120) were randomized equally into three groups: (A) adapalene gel, (B) adapalene gel with the active formulation and (C) adapalene gel with the placebo. The severity of acne, skin bioengineering measurements and skin tolerability were recorded during the study.RESULTSCompared to baseline, the active formulation group showed significant reductions in inflammatory lesions and total lesions at the end of the study without flare-up. Moreover, skin irritations were less detected than in the other two groups by corneometer and transepidermal water loss measurements.CONCLUSIONSThe concomitant usage of adapalene gel and the moisturizer containing licochalcone A, l-carnitine and 1,2-decanediol could reduce undesirable side effects without interfering the efficacy of adapalene. This moisturizer may be superior to placebo to prevent cutaneous irritations and enhance patients' adherence to acne medications.
Author Chularojanamontri, Leena
Kulthanan, Kanokvalai
Varothai, Supenya
Winayanuwattikun, Waranaree
Tuchinda, Papapit
Author_xml – sequence: 1
  givenname: Leena
  surname: Chularojanamontri
  fullname: Chularojanamontri, Leena
  organization: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
– sequence: 2
  givenname: Papapit
  surname: Tuchinda
  fullname: Tuchinda, Papapit
  email: papapitt@gmail.com
  organization: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
– sequence: 3
  givenname: Kanokvalai
  surname: Kulthanan
  fullname: Kulthanan, Kanokvalai
  organization: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
– sequence: 4
  givenname: Supenya
  surname: Varothai
  fullname: Varothai, Supenya
  organization: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
– sequence: 5
  givenname: Waranaree
  surname: Winayanuwattikun
  fullname: Winayanuwattikun, Waranaree
  organization: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26293170$$D View this record in MEDLINE/PubMed
BookMark eNqFUc2OFCEYJGaNO7v6CBouJh7sEYaGbuJlNxv_kk286JnQ8OGidDMC7aZ9Kh9R2pm5eNCEhPqgqr6k6gKdTXEChJ5SsmWUyFdE8lYI1m53hPItJZ3cyf4B2tC2ow3tODtDm5XTrKRzdJHzV0IoE6R_hM53YicZ7cgG_brGNs5DgGYIfrJgX-KkJxtH_3PFP-DOm_pp4lRSDAEszmW2Cy4Ra2MgZ5y_-amOAZIefPBlwVWPwTlvtFlwdHWup_jGTy7ocdQlpgWP0VenVNckvBok0GWEqfwRmAnwvS93mGzpc6yt3usA9e0LhMfoodMhw5PjfYk-v33z6eZ9c_vx3Yeb69vGtEyURvecM6d76K2Tsu1qSGIQTnbGcq65sG5oTQ-OibYTjsJgukG0uq1QVszZJXpx8N2n-H2GXNTos4EQ9ARxzop2grZcsl5W6rMjdR5GsGqf_KjTok4pV8LrA8GkmHMCp4wvuvg1VO2DokStnapTp2rtVB07rWr-l_q04H-6q4Ou5h7TqO9jClYVvYSYXC3Z-LzK_2XxGxKVu10
CitedBy_id crossref_primary_10_1155_2020_2857812
crossref_primary_10_3390_ijms241814177
crossref_primary_10_1001_jamadermatol_2022_3911
crossref_primary_10_1080_09546634_2019_1628173
crossref_primary_10_1111_jdv_20145
crossref_primary_10_1111_jocd_15381
crossref_primary_10_3389_fphar_2020_592654
crossref_primary_10_1007_s13555_023_00943_x
crossref_primary_10_1016_j_annder_2017_08_011
crossref_primary_10_1111_jocd_16212
crossref_primary_10_1089_wound_2024_0148
crossref_primary_10_1111_jocd_13178
crossref_primary_10_1155_2022_3644720
crossref_primary_10_1016_j_intimp_2021_107867
crossref_primary_10_2147_CCID_S422898
crossref_primary_10_1080_15569527_2018_1518329
crossref_primary_10_1111_1346_8138_14314
Cites_doi 10.1111/1346-8138.12520
10.1016/0738-081X(95)00078-T
10.1067/mjd.2003.618
10.1067/S0190-9622(03)01151-4
10.1034/j.1600-0536.2002.460205.x
10.1046/j.1365-2133.1998.1390s2017.x
10.1159/000029945
10.3109/09546634.2012.661037
10.1111/j.1468-3083.2011.04187.x
10.1034/j.1600-0536.2000.042003134.x
10.1016/j.jaad.2007.06.006
10.1007/s00403-006-0654-4
10.1016/j.jaad.2004.10.879
10.1292/jvms.70.841
10.1046/j.1365-2133.1998.1390s2048.x
10.1111/j.1468-3083.2010.03845.x
10.1016/j.nut.2014.10.001
10.3109/09546634.2010.488260
10.1211/jpp.57.12.0017
10.1046/j.1365-2133.2002.04509.x
10.1080/09546630410021702
10.1111/j.1473-2165.2011.00597.x
10.1055/s-2006-960078
10.1016/j.jaad.2009.01.019
10.1016/S0190-9622(97)70051-3
10.1111/jdv.12168
10.1248/cpb.36.2090
10.1016/S0190-9622(97)70052-5
10.1111/j.1365-4632.2009.04068.x
10.1016/j.intimp.2010.02.003
ContentType Journal Article
Copyright 2015 Taylor & Francis. 2015
Copyright_xml – notice: 2015 Taylor & Francis. 2015
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.3109/09546634.2015.1079298
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-1753
EndPage 145
ExternalDocumentID 26293170
10_3109_09546634_2015_1079298
1079298
Genre Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
00X
03L
0YH
29K
36B
4.4
5GY
AAGDL
AALUX
AAMIU
AAPUL
AAQRR
ABBKH
ABDBF
ABEIZ
ABJNI
ABLIJ
ABLKL
ABUPF
ABWVI
ABXYU
ACENM
ACGEJ
ACGFS
ACUHS
ADCVX
ADRBQ
ADXPE
AECIN
AENEX
AEOZL
AFKVX
AFRVT
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AJWEG
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
ALYBC
AMDAE
AQTUD
BABNJ
BLEHA
BOHLJ
CCCUG
CS3
D-I
DKSSO
DU5
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
M4Z
O9-
P2P
RNANH
RVRKI
SV3
TBQAZ
TDBHL
TERGH
TFDNU
TFL
TFW
TUROJ
TUS
UEQFS
V1S
~1N
AAYXX
CITATION
53G
5VS
AALIY
AAORF
AAPXX
ABWCV
ABZEW
ACKZS
ACOPL
ACYZI
ADFOM
ADFZZ
ADYSH
AEIIZ
AFLEI
AJVHN
AWYRJ
BRMBE
CAG
CGR
COF
CUY
CVF
CYYVM
CZDIS
DRXRE
DWTOO
ECM
EIF
GROUPED_DOAJ
JENTW
LJTGL
M44
NPM
NUSFT
QQXMO
7X8
ID FETCH-LOGICAL-c436t-a8553fa8e8df99470156b6f97cd55a56dfb4c8ef36476f1ebc7b64a4f1e9bc753
IEDL.DBID TFW
ISICitedReferencesCount 30
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000369303300009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0954-6634
IngestDate Sun Nov 09 11:30:09 EST 2025
Mon Jul 21 06:04:38 EDT 2025
Tue Nov 18 21:48:21 EST 2025
Sat Nov 29 05:49:08 EST 2025
Mon Oct 20 23:45:42 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords treatment
moisturizer containing licochalcone
Acne
adapalene
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c436t-a8553fa8e8df99470156b6f97cd55a56dfb4c8ef36476f1ebc7b64a4f1e9bc753
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 26293170
PQID 1761459389
PQPubID 23479
PageCount 6
ParticipantIDs crossref_citationtrail_10_3109_09546634_2015_1079298
crossref_primary_10_3109_09546634_2015_1079298
proquest_miscellaneous_1761459389
pubmed_primary_26293170
informaworld_taylorfrancis_310_3109_09546634_2015_1079298
PublicationCentury 2000
PublicationDate 2016-03-03
PublicationDateYYYYMMDD 2016-03-03
PublicationDate_xml – month: 03
  year: 2016
  text: 2016-03-03
  day: 03
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle The Journal of dermatological treatment
PublicationTitleAlternate J Dermatolog Treat
PublicationYear 2016
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References CIT0030
CIT0010
CIT0032
CIT0031
CIT0012
CIT0034
CIT0011
CIT0033
Verschoore M (CIT0002) 1997; 36
Caron D (CIT0007) 1997; 36
CIT0014
CIT0013
CIT0016
CIT0015
CIT0018
CIT0017
CIT0019
Brand B (CIT0005) 2003; 49
CIT0001
CIT0023
CIT0022
Greenspan A (CIT0004) 2003; 72
Feldman SR (CIT0021) 2011; 10
Alirezai M (CIT0020) 2007; 17
CIT0003
CIT0025
CIT0024
CIT0027
CIT0026
CIT0029
CIT0006
CIT0028
CIT0009
CIT0008
References_xml – ident: CIT0024
  doi: 10.1111/1346-8138.12520
– ident: CIT0033
  doi: 10.1016/0738-081X(95)00078-T
– volume: 17
  start-page: 45
  year: 2007
  ident: CIT0020
  publication-title: Eur J Dermatol.
– volume: 10
  start-page: 605
  year: 2011
  ident: CIT0021
  publication-title: J Drugs Dermatol.
– ident: CIT0013
– ident: CIT0001
  doi: 10.1067/mjd.2003.618
– volume: 49
  start-page: S227
  year: 2003
  ident: CIT0005
  publication-title: J Am Acad Dermatol.
  doi: 10.1067/S0190-9622(03)01151-4
– ident: CIT0011
  doi: 10.1034/j.1600-0536.2002.460205.x
– ident: CIT0006
  doi: 10.1046/j.1365-2133.1998.1390s2017.x
– ident: CIT0014
  doi: 10.1159/000029945
– ident: CIT0015
  doi: 10.3109/09546634.2012.661037
– ident: CIT0030
  doi: 10.1111/j.1468-3083.2011.04187.x
– ident: CIT0010
  doi: 10.1034/j.1600-0536.2000.042003134.x
– ident: CIT0017
  doi: 10.1016/j.jaad.2007.06.006
– ident: CIT0029
  doi: 10.1007/s00403-006-0654-4
– ident: CIT0022
  doi: 10.1016/j.jaad.2004.10.879
– volume: 72
  start-page: 76
  year: 2003
  ident: CIT0004
  publication-title: Cutis.
– ident: CIT0034
  doi: 10.1292/jvms.70.841
– ident: CIT0003
  doi: 10.1046/j.1365-2133.1998.1390s2048.x
– ident: CIT0031
  doi: 10.1111/j.1468-3083.2010.03845.x
– ident: CIT0032
  doi: 10.1016/j.nut.2014.10.001
– ident: CIT0016
  doi: 10.3109/09546634.2010.488260
– ident: CIT0028
  doi: 10.1211/jpp.57.12.0017
– ident: CIT0012
  doi: 10.1046/j.1365-2133.2002.04509.x
– ident: CIT0019
  doi: 10.1080/09546630410021702
– ident: CIT0009
  doi: 10.1111/j.1473-2165.2011.00597.x
– ident: CIT0027
  doi: 10.1055/s-2006-960078
– ident: CIT0018
  doi: 10.1016/j.jaad.2009.01.019
– volume: 36
  start-page: S104
  year: 1997
  ident: CIT0002
  publication-title: J Am Acad Dermatol.
  doi: 10.1016/S0190-9622(97)70051-3
– ident: CIT0008
  doi: 10.1111/jdv.12168
– ident: CIT0025
  doi: 10.1248/cpb.36.2090
– volume: 36
  start-page: S110
  year: 1997
  ident: CIT0007
  publication-title: J Am Acad Dermatol.
  doi: 10.1016/S0190-9622(97)70052-5
– ident: CIT0023
  doi: 10.1111/j.1365-4632.2009.04068.x
– ident: CIT0026
  doi: 10.1016/j.intimp.2010.02.003
SSID ssj0013608
Score 2.2242618
Snippet Introduction: Topical retinoids are considered to be the first-line agents and maintenance therapy of acne; however, irritation side effects are major concern...
Topical retinoids are considered to be the first-line agents and maintenance therapy of acne; however, irritation side effects are major concern issues....
INTRODUCTIONTopical retinoids are considered to be the first-line agents and maintenance therapy of acne; however, irritation side effects are major concern...
SourceID proquest
pubmed
crossref
informaworld
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 140
SubjectTerms Acne
Acne Vulgaris - drug therapy
adapalene
Adapalene - therapeutic use
Administration, Topical
Adult
Anti-Inflammatory Agents - therapeutic use
Chalcones - administration & dosage
Dermatologic Agents - therapeutic use
Double-Blind Method
Female
Gels
Humans
Male
Medication Adherence
moisturizer containing licochalcone
Prospective Studies
Skin - pathology
treatment
Young Adult
Title A double-blinded, randomized, vehicle-controlled study to access skin tolerability and efficacy of an anti-inflammatory moisturizer in treatment of acne with 0.1% adapalene gel
URI https://www.tandfonline.com/doi/abs/10.3109/09546634.2015.1079298
https://www.ncbi.nlm.nih.gov/pubmed/26293170
https://www.proquest.com/docview/1761459389
Volume 27
WOSCitedRecordID wos000369303300009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAWR
  databaseName: Taylor & Francis
  customDbUrl:
  eissn: 1471-1753
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0013608
  issn: 0954-6634
  databaseCode: TFW
  dateStart: 19890101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQohLecPyqIwENwy7Gz_iY4VYcYCKQxF7i_wYw4psgrLZSu2v4icy42QLPRQOIOVgR_qcODPOjO3xN4w918kkFawRcx1KIZUH4W0sRNBSQZq6FEKmzH9vjo7K5dJ-HKMJN2NYJc2h00AUkf_VNLidzxlIiMfyNXoFEg0lrYjMFE4_DZp4Ou6Lpp-G5vHi8699BJ1z0hFCEGQ4w3N5Kxes0wXu0ss90GyJFjf_Qx9usf3RDeWHg97cZlegucOufxg32u-yH4c8tltf4zetiVAxvuRo1GK7Xp1R-QS-Ek6Mge41RJ55annfcpdTMPLNt1WD1Rq6gQn8lCOeAzFWuHDK24R1vPqVwP6jWq7zdj9ft6h32w4f03FqYBcHnwGhAU4Lxxz_wS-4i2jo0WgC_wL1PfZp8fb4zTsxJncQQRa6F65UqkiuhDIma6WhI91eJ2tCVMopHZOXoYRE_PY6zcAH47V0EosWy6q4z_aatoGHjBcyAt6YTlNSMqjobbBahXkwpSW2oAmTO6FWYWQ-pwQcdYUzIJJGtZNGRdKoRmlM2Ktz2PeB-uNvAPu7xlR9XnNJQ4IUwv0R-2ynXhUOcNq1cQ202001M-hBKYuO5YQ9GPTu_HXmGr017OKjf3jyY3YDqzrH1RVP2F7fbeEpuxZO-tWmO2BXzbI8yIPqJ2wWHiY
linkProvider Taylor & Francis
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagIMqFZ4GlPIwEN9zubvyIjxViVcR2T4vozXL8gBXZpMpmK5VfxU9kxsn2cSgcQMrBTvQ5jxlnxmP7G0LeyqiicFqxsXQ546IIrNA-Y05yEeLQRucSZf5UzWb58bG-vBcGl1XiGDp2RBHpX42dG4PR-2mIOdT74BZwsJQYEhkJGH8qsPH5TXJLgK1F_vz55OvFTIJMWekQwhDT7eK5vpkr9ukKe-n1PmiyRZP7_-MtHpB7vSdKDzrVeUhuhOoRuXPUz7U_Jr8OqK_XRQmftURORf-egl3z9XLxE8un4TviWL_WvQyeJqpa2tbUpiyMdPVjUUG1DE1HBn5GAU8DklZYd0brCHU42gWDDwCauUwz_nRZg-qtG7hNQ7GBzVL4BHBVoBg7pvAbfketB1sPdjPQb6HcIV8mH-cfDlmf34E5nsmW2VyILNo85D5qzRXu6i5k1Mp5IayQPhbc5SEixb2Mo1A4VUhuORQ1lEX2hGxVdRWeEZpxH-DEcBij4E74QjsthRs7lWskDBoQvpGqcT35OebgKA0MglAaZiMNg9IwvTQGZO8cdtKxf_wNoC-rjGlT2CV2OVIQ90fsm41-GejjOHFjq1CvV2akwIkC5c71gDztFO_8ccYSHDZ4xef_cOfXZPtwfjQ100-zz7vkLlySaZld9oJstc06vCS33Wm7WDWvUt_6DbnIIWg
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagoIoLtDwXKDUS3HC7u_EjPlbAqqjtqocierMcP2BFNqmy2UrlV_ETmXGyhR5KDyDl4CT6nDgz9oztyTeEvJFRReG0YmPpcsZFEVihfcac5CLEoY3OJcr8QzWd5qen-riPJlz0YZU4h44dUUQaq7Fzn_m4m2aYQ70LXgEHQ4krIiMB008FJj6_Te6A6yxRyU8mX35vJMiUlA4hDDHdTzzXV3PFPF0hL73eBU2maPLgPzRig9zv_VC61ynOJrkVqodk_ajfaX9Efu5RXy-LEj5qiYyK_h0Fq-br-ewHls_DN8SxPtK9DJ4molra1tSmHIx08X1WwWkZmo4K_IICngakrLDugtYRzuFoZwzaD3o5T_v9dF6D4i0beExDsYJVIHwCuCpQXDmmMAi_pdaDpQerGejXUD4mnycfT97vsz67A3M8ky2zuRBZtHnIfdSaK_ynu5BRK-eFsEL6WHCXh4gE9zKOQuFUIbnlUNRQFtkTslbVVXhGaMZ9gAvDYYyCO-EL7bQUbuxUrpEuaED4SqjG9dTnmIGjNDAFQmmYlTQMSsP00hiQnUvYWcf9cRNA_6kxpk2LLrHLkIK4v2Jfr9TLQA_HbRtbhXq5MCMFLpTQ4FkOyNNO7y5fZyzBXYMmPv-HJ2-T9eMPE3P4aXrwgtyDOzLF2GUvyVrbLMMWuevO29mieZV61i81OiAa
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+double-blinded%2C+randomized%2C+vehicle-controlled+study+to+access+skin+tolerability+and+efficacy+of+an+anti-inflammatory+moisturizer+in+treatment+of+acne+with+0.1%25+adapalene+gel&rft.jtitle=The+Journal+of+dermatological+treatment&rft.au=Chularojanamontri%2C+Leena&rft.au=Tuchinda%2C+Papapit&rft.au=Kulthanan%2C+Kanokvalai&rft.au=Varothai%2C+Supenya&rft.date=2016-03-03&rft.eissn=1471-1753&rft.volume=27&rft.issue=2&rft.spage=140&rft.epage=145&rft_id=info:doi/10.3109%2F09546634.2015.1079298&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-6634&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-6634&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-6634&client=summon